Regulus Therapeutics (NASDAQ: RGLS) reported Q4 EPS of ($0.38), $0.01 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at less than $100 thousand versus $10.9 million last year,

Cash, cash equivalents and short-term investments were $76.1 million at December 31, 2016, compared with $115.3 million at December 31, 2015.

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.